Emerging Growth Reaffirms Buy-Emerging Rating and $10.00 Price Target for OSR Holdings Following Major Licensing Agreement

Emerging Growth Research has reaffirmed its Buy-Emerging rating and $10.00 price target for OSR Holdings, Inc. following a major non-binding licensing term sheet with BCM Europe AG valued at $815 million for the global development and commercialization of VXM01, an oral T-cell immunotherapy program. The agreement marks a significant inflection point for OSRH and validates management's strategic vision and execution capabilities.